The April 24 termination email sent to all 22 members of the National Science Board cited United States v. Arthrex — the Supreme Court's 2021 decision on the appointment of Patent Trial and Appeal Board judges — as the legal foundation for the firings. [1] Duke Law professor Jeff Powell, in a Friday analysis for Lawfare, identified the mismatch: Arthrex concerned officers whose decisions were not reviewable by a principal officer; the case's remedy was to make those officers removable by the President. National Science Board members were already removable. [2]

The paper's Friday account of the NSB firings as the start of a lost-science thread of its own framed the action as the same legal theory the administration walked through this week with NDAA §1233 and the War Powers Resolution: a binding statutory structure recharacterized as administrative inconvenience. The Powell analysis is the legal critique catching up to the institutional one. Arthrex is the wrong case. It is not the case that authorizes what the email did.

The mechanics matter. Arthrex, decided 5-4 in a fractured opinion led by Chief Justice Roberts, addressed an appointments-clause defect in the Patent Trial and Appeal Board: PTAB judges were "principal officers" under the Constitution's Appointments Clause but had been appointed by the Secretary of Commerce as if they were inferior officers. [3] The Court's remedy was to read the statute as giving the Director of the Patent Office authority to review PTAB decisions — converting the judges from principal to inferior officers and curing the appointments defect prospectively. The remedy did not fire anyone. The remedy did not authorize the President to fire anyone. The remedy converted a structural ambiguity into a clarified hierarchy.

National Science Board members are appointed by the President with Senate confirmation under 42 U.S.C. § 1863 — the National Science Foundation Act of 1950. [4] They serve six-year staggered terms. The statute does not specify removal grounds, which under the Supreme Court's 2020 decision in Seila Law v. CFPB means the President's removal authority is the constitutional default unless Congress specifies otherwise. The NSB is a multi-member advisory board, not an independent regulatory commission, and the Court's Humphrey's Executor exception for independent commissions has, since Seila Law, been narrowed enough that NSB members were already understood to be removable at will. The administration did not need Arthrex to fire them. Arthrex does not say what they say it says.

Powell's read is sharper. "The administration is using Arthrex as if it were a removal case," he wrote. "It is not. It is an appointments case. The remedy in Arthrex would, applied to the NSB, change how new members are confirmed — not whether old members can be terminated. The citation is institutional cover, not legal grounding." [2] The implication is that the firings will withstand judicial review on different grounds — the Seila Law default — but the administration's stated rationale is not the rationale a court would adopt.

Why cite the wrong case? Two readings. The first is operational: Arthrex is recent, fresh, and Republican-Court-authored, and reads in headlines as a strong-executive precedent. The second is strategic: by citing Arthrex, the administration positions the next institutional move — likely a similar action against the National Endowment for the Humanities board, the Smithsonian regents, or the Securities and Exchange Commission — within a single legal frame. The administration is building a doctrine in public. It is using Arthrex as the doctrine's name, not its source.

The replacement appointments clock is the next test. The National Academies of Sciences, Engineering, and Medicine and the American Association for the Advancement of Science are watching for the White House list — the National Science Foundation's own organic act requires the NSB to confirm the NSF Director's major program decisions, and absent a quorum, those decisions cannot legally be ratified. [5] If the White House nominates a slate within thirty days, the operational disruption is minimized. If it does not, the NSF's Q3 grant pipeline begins to clear without statutory cover.

The constitutional question and the operational question are running on different clocks. The constitutional question — whether Arthrex's rationale supports the action — will be answered, if at all, in the federal-court litigation the AAAS general counsel's office has signaled is in preparation. The operational question — whether the NSF can issue grants without a quorum-able board — will be answered in the next forty-five days. Powell's analysis sharpens both.

Five binding statutes recharacterized as administrative inconveniences in one regime-week. Arthrex is the legal vocabulary; the rationale is something else.

-- ANNA WEBER, Berlin